<DOC>
	<DOC>NCT02435108</DOC>
	<brief_summary>This is a pilot study of crizotinib in patients with c-MET positive gastric adenocarcinoma.</brief_summary>
	<brief_title>A Pilot Study of Crizotinib in Patients With c-MET Positive Gastric Adenocarcinoma as a Third-line Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Crizotinib</mesh_term>
	<criteria>1. Provision of fully informed consent prior to any study specific procedures. 2. Patients must be â‰¥20 years of age. 3. Advanced gastric adenocarcinoma (including GEJ) that has progressed during or after second line therapy. 4. cMET positive gastric cancer 5. ECOG PS 02 6. At least one measurable disease 7. Proper organ function 1. severe comorbid illness and/or active infections 2. pregnant or lactating women 3. History of documented congestive heart failure; angina pectoris requiring medication; evidence of tranasmural myocardial infarction on ECG; poorly controlled hypertension; clinically significant valvular heart disease; or high risk of uncontrollable arrhythmia 4. active CNS metastases not controllable with radiotherapy or corticosteroids (however, CNS metastases (except for leptomeningeal seeding) are allowed if controlled by gamma knife surgery or surgery or radiotherapy or steroid) 5. known history of hypersensitivity to study drugs</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>MET poisitivity is defined as at least half of tumor cells show weak, moderate or high staining</keyword>
</DOC>